Illumina Inc. (Nasdaq: ILMN)

https://www.illumina.com

Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients. *

	Start	1998-04-01 established
	Group	Illumina (Group)
	Industry	Genome Analyzer
	Industry 2	BeadArray technology (Illumina)
	Person	Thaysen, Jacob (Illumina 202309– CEO before Agilent + Dako)

	Region	San Diego, CA
	Country	United States (USA)
	Street	9885 Towne Centre Drive
	City	92121 San Diego, CA
	Tel	+1-858-202-4566
		Address record changed: 2024-01-05

Basic data	Employees	F: 1,001 to 5,000 (2012-01-25)
	Currency	USD
	Annual sales	3,333,000,000 (revenue, total, consolidated (2018) 2018-12-31)
	Profit	782,000,000 (2018-12-31)
	Cash	1,144,000,000 (2018-12-31)

		* Document for »About Section«:

		Record changed: 2024-01-05